# Trevi Therapeutics (TRVI) — Earnings

TRVI · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/trvi/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.11 |
| EPS estimate | −$0.11 |
| EPS surprise | −0.46% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 6, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1563880/000119312526338023/trvi-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/951aea8f-ad0d-1e7c-1a94-36b140b42fdb.html) |

Trevi Therapeutics reported Q2 2026 results on August 6, 2026. It posted a loss of $0.11 per share, level with the rounded estimate of a $0.11 loss; the source records a slight miss of 0.46%. The table shows no revenue for this or any other quarter. Compared with Q2 2025, the loss widened from $0.09 per share.

Trevi has posted a loss in all 20 quarters in the table. Losses were largest at the start of the record, $0.34 per share in Q3 2021, and narrowed through 2022. Annual losses were $0.56 per share in 2022, $0.29 in 2023, $0.47 in 2024 and $0.32 in 2025. The first half of 2026 adds up to a $0.20 loss, against $0.18 a year earlier. The smallest quarterly losses here were $0.06, in Q4 2022, Q1 2023 and Q4 2025. Trevi's result was better than the estimate in 15 of the last 20 quarters.

Trevi reported Q3 between November 6 and November 13 in each of the past five years. That points to early or mid-November 2026 for the next report. It will show how the quarterly loss compares with the range of $0.06 to $0.11 seen over the last six quarters.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 6, 2026 | −$0.11 | −$0.11 | -0.46% | — | — |
| Q1 2026 | May 5, 2026 | −$0.08 | −$0.09 | -18.89% | — | — |
| Q4 2025 | Mar 17, 2026 | −$0.10 | −$0.06 | 37.89% | — | — |
| Q3 2025 | Nov 13, 2025 | −$0.10 | −$0.08 | 18.62% | — | — |
| Q2 2025 | Aug 7, 2025 | −$0.10 | −$0.09 | 13.63% | — | — |
| Q1 2025 | May 8, 2025 | −$0.12 | −$0.09 | 26.83% | — | — |
| Q4 2024 | Mar 18, 2025 | −$0.13 | −$0.11 | 14.20% | — | — |
| Q3 2024 | Nov 6, 2024 | −$0.12 | −$0.13 | -8.79% | — | — |
| Q2 2024 | Aug 8, 2024 | −$0.11 | −$0.12 | -10.50% | — | — |
| Q1 2024 | May 7, 2024 | −$0.09 | −$0.11 | -26.00% | — | — |
| Q4 2023 | Mar 20, 2024 | −$0.09 | −$0.08 | 12.76% | — | — |
| Q3 2023 | Nov 9, 2023 | −$0.09 | −$0.08 | 12.76% | — | — |
| Q2 2023 | Aug 10, 2023 | −$0.09 | −$0.07 | 17.65% | — | — |
| Q1 2023 | May 11, 2023 | −$0.07 | −$0.06 | 18.81% | — | — |
| Q4 2022 | Mar 16, 2023 | −$0.11 | −$0.06 | 43.40% | — | — |
| Q3 2022 | Nov 10, 2022 | −$0.13 | −$0.12 | 7.69% | — | — |
| Q2 2022 | Aug 11, 2022 | −$0.17 | −$0.14 | 18.84% | — | — |
| Q1 2022 | May 12, 2022 | −$0.26 | −$0.24 | 8.85% | — | — |
| Q4 2021 | Mar 17, 2022 | −$0.30 | −$0.28 | 5.08% | — | — |
| Q3 2021 | Nov 10, 2021 | −$0.40 | −$0.34 | 13.92% | — | — |

## Frequently Asked Questions

### When did Trevi Therapeutics (TRVI) last report earnings?

Trevi Therapeutics last reported on Aug 6, 2026, covering fiscal Q2 2026.

### Did TRVI beat earnings estimates?

No. Trevi Therapeutics reported EPS of −$0.11 for Q2 2026 against a −$0.11 estimate — a 0.46% miss.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).